Plasma parathyroid hormone related-protein (PTHrP) may inhibit the calium-lowering effect of bisphosphonate therapy. In this prospective study we examined the relationship between plasma PTHrP levels, renal tubular markers of calcium reabsorption, and the effectiveness of intravenous bisphosphonate therapy (IVBPT) in lowering serum calcium in patients with hypercacaemia of malignancy (HM), with and without bone metastases. Thirty-five symptomatic hypercalcaemic patients (17 without and 18 with bone metastases)
Parathyroid hormone-related protein has been localised in a wide range of solid tumours, as well as fetal and normal adult tissues (Danks et al., 1989; Kramer et al., 1991; . Increased concentrations of plasma PTHrP in hypercalcaemia of malignancy (HM) have been found in up to 88% of patients (Grill et al., 1991; Ratcliffe et al., 1992) , and there is overwhelming evidence that tumourderived PTHrP is the major hypercalcaemic factor in this paraneoplastic syndrome (Martin et al., 1989) . PTHrP occurs in three isoforms of 139, 141 and 173 amino acids and shares 70% homology with parathyroid hormone (PTH) at their extreme amino termini, enabling PTHrP to interact with classical PTH receptors in bone and kidney, which results in activation of adenylate cyclase (Juppner et al., 1988) . PTHrP has similar bioactivity to PTH both in vivo and in vitro: when infused in animal studies it produces hypercalcaemia and increases bone resorption, renal tubular reabsorption of calcium and nephrogenous cAMP, while reducing renal tubular reabsorption of phosphate (Martin et al., 1989) . In patients with solid tumours there is evidence that circulating PTHrP contributes to the hypercalcaemia in patients with bone metastases as well as those with no bone involvement (Grill et al., 1991) . The treatment of choice for patients presenting with hypercalcaemia of malignancy is intravenous bisphosphonate therapy (Thiebald et al., 1986; Ralston et al., 1987 Ralston et al., , 1989 . Bisphosphonates are stable pyrophosphate analogues which bind to hydroxyapatite in the bone matrix, and inhibit osteoclast recruitment and function. Pamidronate (3-amino-1-hydroxypropyl-idene-l,I-bisphosphonate) is a second-generation drug which is a potent inhibitor of osteoclastic bone resorption (Body et al., 1986) . Initial studies have shown that plasma PTHrP levels are unaffected by treatment (Grill et al., 1992; Blind et al., 1993; Body et al., 1993) . These studies also indicated that the response to intravenous bisphosphonate therapy (IVBPT) is influenced by the initial plasma PTHrP concentration, with patients with the highest levels of plasma PTHrP showing the poorest response (Blind et al., 1993; Body et al., 1993) . Correlations between initial plasma PTHrP concentrations and renal tubular handling of phosphate (Gurney et al., 1993) and calcium (Body et al., 1993) suggested that the renal action of PTHrP is responsible for the poor response to IVBPT. The aim of this study was to compare plasma PTHrP concentrations, renal tubular markers of calcium reabsorption, and the effectiveness of IVBPT in lowering serum calcium in patients with hypercalcaemia of malignancy and bone metastases and in a similar group in whom the mechanism of the hypercalcaemia was predominantly humoral.
Patets and methods

Patients
Thirty-five patients with HM were collected prospectively to study the effects of intravenous bisphosphonate therapy in a routine clinical setting. Any patient noted to have received previous or concurrent treatment affecting calcium metabolism was excluded, i.e. radiotherapy or chemotherapy within an 8 week period, or any previous bisphosphonate therapy. Hypercalcaemia was defined as a serum calcium of greater than 2.6 mmol 1', when adjusted for the serum albumin (Gardner et al., 1981) . The sites of the primary tumours were breast (10), lung (8), female genitourinary tract (6), haematological malignancies (3), head and neck squamous cancers (3), metastatic adenocarcinoma assumed to be derived from pancreas (2), bladder (1) and disseminated malignancy from an unknown primary (2). Two (n = 4) and 60mg (n = 3) was given up to a maximum of 120 mg of pamidronate per patient.
All baseline blood samples were collected following the rehydration period, immediately before bisphosphonate therapy was commenced. Venous blood for assay of plasma PTHrP was collected in the presence of EDTA and 2,000 IU of apoprotinin and separated within 15 min. Plasma PTHrP 1-86 was assayed by an established two-site immunoradiometric assay (IRMA) with a detection limit of 0.23 pmol 1-1 (Ratcliffe et al., 1991) . PTHrP 1-86 levels in normocacaemic controls are <0.23pmoll-' (Ratcliffe et al., 1991) . Intact serum PTH 1-84 was measured by a two-site IRMA (Nicholls Institute) and levels less than 1.5 pmol 1' were considered suppressed or subnormal. Urine was collected between the hours of 10.00 and 12.00. Calcium excretion (CaE) was caculated by dividing urinary calcium by urinary creatinine and multiplying by the serum creatinine and was plotted against the serum calcium to assess renal tubular reabsorption of calcium (Peacock et al., 1969 (Table I) .
Eiseassiom
There were significant differences in the effectiveness of IVBPT and the biochemical responses in patients with and without bone metastases, despite the initial serum calcium concentrations being similar in the two groups. Serum calcium fell significantly following either a single or repeated infusion of bisphosphonate and was normalised in 71% of patients overall, a typical response rate in such patients (Dodwell et al., 1991) . However, a higher proportion of patients with humoral hypercacaemia required a second treatment of IVBPT (47% vs 6%), and the proportion achieving normocacaemia was lower (53% vs 94%), a finding previously noted by others (Dodwell et al., 1991) . Plsma PTHrP 1-86 measured by two-site IRMA was higher before treatment in humoral HM, confirming earlier studies which measured PTHrP 50-69 and 1-74 (Burtis et al., 1990; Dodwell et al., 1991) . Although several earlier studies found no change in plasma PTHrP levels in patients with hypercalcaemia of malignancy following IVBPT (Grill et al., 1992; Blind et al., 1993; Body et al., 1993; Gurney et al., 1993) , we have found a small fall in plasma PTHrP which was significant only in patients with humoral HM. The explanation for this apparent decline in plasma PTHrP during IVBPT treatment is unclear. The PTHrP IRMA used in this study has been extensively validated in clinical studies and measures increased PTHrP 1-86 levels in approximately 90% of patients with hypercakcemia of malignancy (Ratcliffe et al., 1991 (Ratcliffe et al., , 1992 . Patients were fully rehydrated before therapy, and it is possible that treatment was accompanied by changes in the distribution, metabolism or even secretion of PTHrP. In vitro studies using Leydig tumour cells have shown that high extracellular calcium may increase secretion of PTHrP (Rizzoli et al., 1989 ), but there is no direct evidence that calcium regulates tumour secretion of PTHrP. The decrease found in urinary cAMP excretion foliowing treatment could in part reflect the obsrved fall in plasma PTHrP. Biochemical parameters of renal tubular handling of calcium and phosphate and nephrogenous cAMP provide indirect indices of the renal actions of tumour-derived PTHlike bioactivity (Ralston et al., 1987; Gallacher et al., 1992) . These studies and others have provided indirect evidence that mechanisms involving tumour-derived PTHrP were responsible for hypercalcemia in a high proportion of patients with HM. Our finding that plasma PTHrP levels were higher in patients with humoral HM is consistent with previous data which indicated that renal PTH-like activity was also highest in patients without bone metastases (Ralston et al., 1987) and may explain why the renal component of HM is unresponsive to bone-specific agents. The poor response to IVBPT in patients with humoral malignancy may reflect the high circulating levels of PTHrP in this group, and its effect in promoting renal reabsorption of calcium. A signant inverse relationship between plasma PTHrP 50-69 levels and the response to pamidronate as judged by the time taken to achieve normocacaemia has been observed (Dodwell et al., 1991) , while elevated plasma PTHrP 53-84 was associated with a poor response to IVBPT in five out of six patients (Blind et al., 1993) . The biological effects of PTHrP on the renal tubule appear to be mediated via the PTH receptor, and a synthetic analogue, Tyr34 bPTH(7-34)NH2, can inhibit the renal effects of PTH as a result of direct competition at the PTH-specific receptor site (Horiuchi et al., 1983) .
Injection of this analogue in fetal lambs has been shown to inhibit the renal effects of PTHrP (Davioco et al., 1992) . Antibodies to PTHrP 1-34 have also been shown to lower serum calcium in a tumour model of hypercakcemia in the athymic mouse (Kukreja et al., 1988) . Although it would be useful to be able to predict the effective dose or likely response of each patient to IVBPT, our data suggest that no single biochemical or clinical parameter is likely to be reliable. In the patients studied we found no correlation between plasma PTHrP and the magnitude of fall or nadir of serum calcium. Despite this, however, basal plasma PTHrP levels were higher in patients remaining hypercacaemic. 
